Summit Therapeutics
SMMT
Summit Therapeutics (SMMT) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.28
- EPS estimate
- −$0.27
- EPS surprise
- −2.04%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Jul 23, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 23, 2026 | −$0.27 | −$0.28 | −2.04% | $0.00 | SEC |
| Q4 2025 | Feb 23, 2026 | −$0.09 | −$0.29 | −233.72% | $0.00 | SEC |
| Q3 2025 | Oct 20, 2025 | −$0.17 | −$0.31 | −82.25% | $0.00 | SEC |
| Q2 2025 | Aug 11, 2025 | −$0.09 | −$0.76 | −737.00% | $0.00 | SEC |
| Q1 2025 | May 1, 2025 | −$0.09 | −$0.09 | +3.23% | $0.00 | SEC |
| Q4 2024 | Feb 24, 2025 | −$0.08 | −$0.08 | +2.20% | $0.00 | SEC |
| Q3 2024 | Oct 30, 2024 | −$0.07 | −$0.08 | −19.76% | $0.00 | SEC |
| Q2 2024 | Aug 6, 2024 | −$0.06 | −$0.05 | +19.22% | $0.00 | SEC |
| Q1 2024 | May 1, 2024 | −$0.06 | −$0.06 | +0.00% | $0.00 | SEC |
| Q4 2023 | Feb 20, 2024 | $0.00 | −$0.05 | +0.00% | $0.00 | SEC |
| Q1 2023 | May 11, 2023 | $0.00 | −$1.43 | +0.00% | $0.00 | SEC |
| Q4 2022 | Mar 9, 2023 | −$0.26 | −$0.07 | +73.08% | $5,000.00 | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.26 | −$0.14 | +46.15% | $220,000.00 | SEC |
| Q2 2022 | Aug 11, 2022 | −$0.27 | −$0.17 | +37.04% | $235,000.00 | SEC |
| Q1 2022 | May 11, 2022 | −$0.28 | −$0.22 | +21.43% | $250,000.00 | SEC |
| Q4 2021 | Mar 17, 2022 | −$0.27 | −$0.28 | −3.70% | $251,000.00 | SEC |
| Q3 2021 | Nov 15, 2021 | −$0.29 | −$0.20 | +31.03% | $1.3M | SEC |
| Q2 2021 | Aug 11, 2021 | −$0.18 | −$0.27 | −50.00% | $57,000.00 | — |
| Q1 2021 | May 17, 2021 | −$0.17 | −$0.21 | −23.53% | $192,000.00 | SEC |
| Q4 2020 | Mar 17, 2021 | −$0.21 | −$0.18 | +14.29% | $185,000.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Summit Therapeutics (SMMT) last report earnings?
Summit Therapeutics last reported on Jul 23, 2026, covering fiscal Q2 2026.
Did SMMT beat earnings estimates?
No. Summit Therapeutics reported EPS of −$0.28 for Q2 2026 against a −$0.27 estimate — a 2.04% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.